Journal of Preventive Medicine and Public Health

The Korean Society for Preventive Medicine (대한예방의학회)
권호 표지
DOI QR코드

DOI QR Code

The Prevalence of Cardiovascular Disease Risk Factors and the Framingham Risk Score in Patients Undergoing Percutaneous Intervention Over the Last 17 Years by Gender: Time-trend Analysis From the Mayo Clinic PCI Registry

  • Lee, Moo-Sik (Department of Preventive Medicine, Konyang University College of Medicine) ;
  • Flammer, Andreas J. (Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic) ;
  • Kim, Hyun-Soo (Department of Preventive Medicine, Konyang University College of Medicine) ;
  • Hong, Jee-Young (Department of Preventive Medicine, Konyang University College of Medicine) ;
  • Li, Jing (Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic) ;
  • Lennon, Ryan J. (Division of Biomedical Statistics and Informatics, Mayo Clinic) ;
  • Lerman, Amir (Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic)
  • Received : 2014.03.12
  • Accepted : 2014.06.06
  • Published : 2014.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: This study aims to investigate trends of cardiovascular disease (CVD) risk factor profiles over 17 years in percutaneous coronary intervention (PCI) patients at the Mayo Clinic. Methods: We performed a time-trend analysis within the Mayo Clinic PCI Registry from 1994 to 2010. Results were the incidence and prevalence of CVD risk factors as estimate by the Framingham risk score. Results: Between 1994 and 2010, 25 519 patients underwent a PCI. During the time assessed, the mean age at PCI became older, but the gender distribution did not change. A significant trend towards higher body mass index and more prevalent hypercholesterolemia, hypertension, and diabetes was found over time. The prevalence of current smokers remained unchanged. The prevalence of ever-smokers decreased among males, but increased among females. However, overall CVD risk according to the Framingham risk score (FRS) and 10-year CVD risk significantly decreased. The use of most of medications elevated from 1994 to 2010, except for ${\beta}$-blockers and angiotensin converting enzyme inhibitors decreased after 2007 and 2006 in both baseline and discharge, respectively. Conclusions: Most of the major risk factors improved and the FRS and 10-year CVD risk declined in this population of PCI patients. However, obesity, history of hypercholesterolemia, hypertension, diabetes, and medication use increased substantially. Improvements to blood pressure and lipid profile management because of medication use may have influenced the positive trends.

Keywords

References

  1. Wijeysundera HC, Machado M, Farahati F, Wang X, Witteman W, van der Velde G, et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. JAMA 2010;303(18):1841-1847. https://doi.org/10.1001/jama.2010.580
  2. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. Deaths: final data for 2006. Natl Vital Stat Rep 2009;57(14):1-134.
  3. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364(9438):937-952. https://doi.org/10.1016/S0140-6736(04)17018-9
  4. Arnett DK, McGovern PG, Jacobs DR Jr, Shahar E, Duval S, Blackburn H, et al. Fifteen-year trends in cardiovascular risk factors (1980-1982 through 1995-1997): the Minnesota Heart Survey. Am J Epidemiol 2002;156(10):929-935. https://doi.org/10.1093/aje/kwf133
  5. Khawaja FJ, Rihal CS, Lennon RJ, Holmes DR, Prasad A. Temporal trends (over 30 years), clinical characteristics, outcomes, and gender in patients$\leq$50 years of age having percutaneous coronary intervention. Am J Cardiol 2011;107(5):668-674. https://doi.org/10.1016/j.amjcard.2010.10.044
  6. Labarthe DR. Epidemiology and prevention of cardiovascular diseases: a global challenge. 2nd ed. Sudbury: Jones and Bartlett Publishers; 2011, p. 74-79.
  7. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97(18):1837-1847. https://doi.org/10.1161/01.CIR.97.18.1837
  8. Hoffman SJ, Holmes DR Jr, Rabinstein AA, Rihal CS, Gersh BJ, Lennon RJ, et al. Trends, predictors, and outcomes of cerebrovascular events related to percutaneous coronary intervention: a 16-year single-center experience. JACC Cardiovasc Interv 2011;4(4):415-422. https://doi.org/10.1016/j.jcin.2010.11.010
  9. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics: 2012 update. A report from the American Heart Association. Circulation 2012;125(1):e2-e220. https://doi.org/10.1161/CIR.0b013e318245fac5
  10. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117(6):743-753. https://doi.org/10.1161/CIRCULATIONAHA.107.699579
  11. Rubinshtein R, Yang EH, Rihal CS, Prasad A, Lennon RJ, Best PJ, et al. Coronary microcirculatory vasodilator function in relation to risk factors among patients without obstructive coronary disease and low to intermediate Framingham score. Eur Heart J 2010;31(8):936-942. https://doi.org/10.1093/eurheartj/ehp459
  12. Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008;358(13):1336-1345. https://doi.org/10.1056/NEJMoa072100
  13. Hasdai D, Bell MR, Grill DE, Berger PB, Garratt KN, Rihal CS, et al. Outcome>or=10 years after successful percutaneous transluminal coronary angioplasty. Am J Cardiol 1997;79(8):1005-1011. https://doi.org/10.1016/S0002-9149(97)00038-6
  14. Knopp RH, Aikawa K. Estrogen, female gender, and heart disease. In: Topol EJ, Califf RM, editors. Textbook of cardiovascular medicine. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2002, p. 175.
  15. Tsang TS, Barnes ME, Gersh BJ, Hayes SN. Risks of coronary heart disease in women: current understanding and evolving concepts. Mayo Clin Proc 2000;75(12):1289-1303. https://doi.org/10.4065/75.12.1289
  16. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003;290(7):898-904. https://doi.org/10.1001/jama.290.7.898
  17. O'Keefe JH, Carter MD, Lavie CJ. Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach. Mayo Clin Proc 2009;84(8):741-757. https://doi.org/10.4065/84.8.741
  18. Fiebach NH, Hebert PR, Stampfer MJ, Colditz GA, Willett WC, Rosner B, et al. A prospective study of high blood pressure and cardiovascular disease in women. Am J Epidemiol 1989;130(4):646-654. https://doi.org/10.1093/oxfordjournals.aje.a115386
  19. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289(19):2560-2572. https://doi.org/10.1001/jama.289.19.2560
  20. Glaser R, Herrmann HC, Murphy SA, Demopoulos LA, DiBattiste PM, Cannon CP, et al. Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA 2002;288(24):3124-3129. https://doi.org/10.1001/jama.288.24.3124
  21. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113(19):2363-2372. https://doi.org/10.1161/CIRCULATIONAHA.106.174516
  22. Lavie CJ, Milani RV. Shedding light on high-density lipoprotein cholesterol: the post-ILLUMINATE era. J Am Coll Cardiol 2008;51(1):56-58. https://doi.org/10.1016/j.jacc.2007.08.055
  23. Bybee KA, Lee JH, O'Keefe JH. Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin. Curr Med Res Opin 2008;24(4):1217-1229. https://doi.org/10.1185/030079908X292001
  24. Conaway DG, O'Keefe JH, Reid KJ, Spertus J. Frequency of undiagnosed diabetes mellitus in patients with acute coronary syndrome. Am J Cardiol 2005;96(3):363-365. https://doi.org/10.1016/j.amjcard.2005.03.076
  25. Burke JP, O'Brien P, Ransom J, Palumbo PJ, Lydick E, Yawn BP, et al. Impact of case ascertainment on recent trends in diabetes incidence in Rochester, Minnesota. Am J Epidemiol 2002;155(9):859-865. https://doi.org/10.1093/aje/155.9.859
  26. Gandhi GY, Roger VL, Bailey KR, Palumbo PJ, Ransom JE, Leibson CL. Temporal trends in prevalence of diabetes mellitus in a population-based cohort of incident myocardial infarction and impact of diabetes on survival. Mayo Clin Proc 2006;81(8):1034-1040. https://doi.org/10.4065/81.8.1034
  27. Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA 1991;265(5):627-631. https://doi.org/10.1001/jama.1991.03460050081025
  28. Keil U, Liese AD, Hense HW, Filipiak B, Doring A, Stieber J, et al. Classical risk factors and their impact on incident non-fatal and fatal myocardial infarction and all-cause mortality in southern Germany. Results from the MONICA Augsburg cohort study 1984-1992. Monitoring Trends and Determinants in Cardiovascular Diseases. Eur Heart J 1998;19(8):1197-1207. https://doi.org/10.1053/euhj.1998.1089
  29. Gregg EW, Cheng YJ, Cadwell BL, Imperatore G, Williams DE, Flegal KM, et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA 2005;293(15):1868-1874. https://doi.org/10.1001/jama.293.15.1868
  30. Jousilahti P, Tuomilehto J, Vartiainen E, Pekkanen J, Puska P. Body weight, cardiovascular risk factors, and coronary mortality: 15-year follow-up of middle-aged men and women in eastern Finland. Circulation 1996;93(7):1372-1379. https://doi.org/10.1161/01.CIR.93.7.1372
  31. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999;341(15):1097-1105. https://doi.org/10.1056/NEJM199910073411501
  32. Madala MC, Franklin BA, Chen AY, Berman AD, Roe MT, Peterson ED, et al. Obesity and age of first non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 2008;52(12):979-985. https://doi.org/10.1016/j.jacc.2008.04.067
  33. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002;288(14):1723-1727. https://doi.org/10.1001/jama.288.14.1723
  34. Organisation for Economic Cooperation and Development. Health at a glance 2011: OECD indicators. Paris: OECD Publishing; 2011, p. 8.
  35. White HD, Chew DP, Dauerman HL, Mahaffey KW, Gibson CM, Stone GW, et al. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J 2012;163(2):182-190. https://doi.org/10.1016/j.ahj.2011.11.001
  36. Perschbacher JM, Reeder GS, Jacobsen SJ, Weston SA, Killian JM, Slobodova A, et al. Evidence-based therapies for myocardial infarction: secular trends and determinants of practice in the community. Mayo Clin Proc 2004;79(8):983-991. https://doi.org/10.4065/79.8.983
  37. Chandra NC, Ziegelstein RC, Rogers WJ, Tiefenbrunn AJ, Gore JM, French WJ, et al. Observations of the treatment of women in the United States with myocardial infarction: a report from the National Registry of Myocardial Infarction-I. Arch Intern Med 1998;158(9):981-988. https://doi.org/10.1001/archinte.158.9.981
  38. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366(9496):1545-1553. https://doi.org/10.1016/S0140-6736(05)67573-3
  39. Agency for Healthcare Research and Quality. Comparative effectiveness of angiotensin converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease. Rockville: Agency for Healthcare Research and Quality; 2009, p. 2.
  40. Catanzaro DF, Frishman WH. Angiotensin receptor blockers for management of hypertension. South Med J 2010;103(7):669-673. https://doi.org/10.1097/SMJ.0b013e3181e1e2da

Cited by

  1. Clinical Outcomes According to Diabetic Status in Patients Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents : Prespecified Subgroup Analysis vol.8, pp.6, 2014, https://doi.org/10.1161/circinterventions.114.002319
  2. Cardiovascular manifestations of renovascular hypertension in diabetic mice vol.4, pp.None, 2016, https://doi.org/10.7717/peerj.1736
  3. Use of Global Risk Score for Cardiovascular Evaluation of Rural Workers in Southern Brazil vol.2018, pp.None, 2014, https://doi.org/10.1155/2018/3818065
  4. Trends of Cardiovascular Risk Factors in Patients With Acute Myocardial Infarction: Soroka Acute Myocardial Infarction II (SAMI II) Project vol.70, pp.6, 2019, https://doi.org/10.1177/0003319718816479
  5. Sedentary lifestyle and Framingham risk scores: a population-based study in Riyadh city, Saudi Arabia vol.19, pp.None, 2019, https://doi.org/10.1186/s12872-019-1048-9
  6. Temporal trends of patients with acute coronary syndrome and multi-vessel coronary artery disease - from the ACSIS registry vol.304, pp.None, 2014, https://doi.org/10.1016/j.ijcard.2020.01.040